MBRX
Moleculin Biotech, Inc. NASDAQ Listed Jun 2, 2016$2.46
Mkt Cap $3.0M
52w Low $1.79
2.5% of range
52w High $28.60
50d MA $2.35
200d MA $7.63
P/E (TTM)
-0.1x
EV/EBITDA
-1.2x
P/B
2.0x
Debt/Equity
0.0x
ROE
-223.6%
P/FCF
-1.7x
RSI (14)
—
ATR (14)
—
Beta
1.67
50d MA
$2.35
200d MA
$7.63
Avg Volume
162.9K
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
5300 Memorial Drive · Houston, TX 77007 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 20, 2026 | AMC | -7.77 | 2.61 | +133.6% | 2.06 | +2.9% | +1.9% | +7.1% | +10.7% | -2.4% | +0.4% | — |
| Nov 13, 2025 | AMC | -5.00 | -3.25 | +35.0% | 11.35 | -5.0% | -4.4% | -2.2% | -1.0% | +4.4% | -3.8% | — |
| Aug 12, 2025 | AMC | -9.75 | -12.25 | -25.6% | 16.55 | +1.2% | +1.9% | -4.0% | +5.3% | -11.0% | -1.8% | — |
| May 13, 2025 | AMC | -17.75 | -17.25 | +2.8% | 26.75 | -4.7% | -7.2% | -8.2% | +3.1% | +5.7% | -1.4% | — |
| Mar 21, 2025 | AMC | -1.54 | -0.37 | +76.0% | 27.25 | +1.8% | -2.8% | +8.5% | -7.0% | -1.9% | -1.0% | — |
| Nov 11, 2024 | AMC | -2.44 | -2.85 | -16.8% | 62.75 | +2.8% | +5.2% | -4.9% | +23.1% | -12.3% | -7.0% | — |
| Aug 13, 2024 | AMC | -52.50 | -55.75 | -6.2% | 58.75 | +6.4% | +6.4% | -10.8% | +9.4% | -1.6% | +7.1% | — |
| May 10, 2024 | AMC | -89.75 | -50.50 | +43.7% | 119.00 | +2.9% | -1.9% | +3.9% | +1.4% | +2.2% | +1.0% | — |
| Mar 22, 2024 | AMC | -3.05 | -5.02 | -64.6% | 142.50 | +5.3% | -7.9% | -10.9% | +18.4% | +6.7% | -4.1% | — |
| Nov 13, 2023 | AMC | -78.71 | -71.21 | +9.5% | 216.00 | -5.0% | -4.5% | +3.6% | +7.1% | -3.4% | -8.4% | — |
| Aug 11, 2023 | AMC | -104.95 | -74.96 | +28.6% | 231.50 | +0.0% | +0.8% | -3.5% | -2.9% | -1.1% | -3.9% | — |
| May 11, 2023 | AMC | -93.70 | -104.95 | -12.0% | 282.00 | -0.2% | -11.3% | -7.7% | -0.9% | +4.4% | +0.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.10 | $2.15 | +2.4% | +7.1% | +10.7% | -2.4% | +0.4% | -8.2% |
| Dec 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.83 | $4.96 | +2.7% | +3.5% | -0.4% | -9.6% | +4.2% | -11.7% |
| Sep 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.17 | $10.25 | +0.8% | -6.3% | -1.4% | -3.2% | +2.1% | +0.8% |
| Aug 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.64 | $13.25 | -2.9% | +11.3% | -35.2% | -0.2% | -3.4% | -0.9% |
| Jun 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.65 | $17.00 | +2.1% | -12.4% | -54.2% | +2.5% | +10.8% | -3.0% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.50 | $27.25 | +2.8% | +8.5% | -7.0% | -1.9% | -1.0% | -6.4% |
| Mar 25 | Maxim Group | Upgrade | Hold → Buy | — | $26.50 | $27.25 | +2.8% | +8.5% | -7.0% | -1.9% | -1.0% | -6.4% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.25 | $27.75 | +1.8% | -2.8% | +8.5% | -7.0% | -1.9% | -1.0% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.25 | $31.25 | -3.1% | -10.9% | -6.1% | +7.4% | -5.2% | +1.8% |
| Nov 12 | Maxim Group | Maintains | Buy → Buy | — | $62.75 | $64.50 | +2.8% | +5.2% | -4.9% | +23.1% | -12.3% | -7.0% |
| Apr 12 | Roth MKM | Maintains | Buy → Buy | — | $119.25 | $120.50 | +1.0% | -2.9% | -3.7% | -4.0% | +0.0% | +5.6% |
| Mar 26 | Maxim Group | Maintains | Buy → Buy | — | $131.25 | $123.75 | -5.7% | -10.9% | +18.4% | +6.7% | -4.1% | -3.9% |
| Apr 18 | Roth MKM | Maintains | Buy → Buy | — | $350.75 | $356.25 | +1.6% | -8.3% | -6.7% | -2.1% | +0.0% | -4.3% |
| Mar 24 | Oppenheimer | Maintains | Outperform → Outperform | — | $353.75 | $363.75 | +2.8% | +7.1% | -4.6% | -1.4% | -4.9% | +4.1% |
| Oct 17 | Oppenheimer | Maintains | Outperform → Outperform | — | $2340.00 | $2520.00 | +7.7% | +3.8% | -0.9% | +0.9% | +5.6% | -2.6% |
| Nov 14 | Maxim Group | Maintains | Buy → Buy | — | $3037.50 | $3082.50 | +1.5% | -5.9% | +8.7% | +0.7% | +0.7% | -2.1% |
No insider trades available.
8-K · 7.01
! Medium
Moleculin Biotech, Inc. -- 8-K 7.01: Regulation FD Disclosure
May 13
8-K · 7.01
! Medium
Moleculin Biotech, Inc. -- 8-K 7.01: Regulation FD Disclosure
May 12
8-K · 7.01
! Medium
Moleculin Biotech, Inc. -- 8-K 7.01: Regulation FD Disclosure
Moleculin Biotech's liposomal Annamycin demonstrated significant tumor inhibition and 60% median survival extension in pancreatic cancer models, potentially strengthening clinical development prospects for this non-cardiotoxic anthracycline candidate.
Apr 23
8-K
Unknown — 8-K Filing
Moleculin Biotech's shareholders rejected a name change, suggesting internal disagreement about the company's direction and potentially signaling uncertainty about management's strategic vision or rebranding plans.
Apr 15
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Moleculin Biotech reached a 45-subject enrollment milestone in its pivotal MIRACLE trial for Annamycin, signaling clinical progress that could validate the drug candidate and potentially drive near-term regulatory catalysts.
Mar 23
8-K
Unknown — 8-K Filing
Moleculin's preliminary 40% complete response rate in early MIRACLE trial data suggests potential efficacy in difficult-to-treat AML, supporting upcoming mid-2026 interim results that could significantly impact stock valuation.
Mar 19
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
MBRX disclosed material non-public information to select parties, potentially creating information asymmetry that could disadvantage other investors and warrant SEC scrutiny of fair disclosure compliance.
Mar 19
8-K · 1.01
!! High
Moleculin Biotech, Inc. -- 8-K 1.01: Material Agreement
Moleculin Biotech registered shares underlying existing warrants on Form S-1, enabling warrant holders to exercise and resell shares without registration delays.
Feb 20
8-K · 7.01
! Medium
Moleculin Biotech, Inc. -- 8-K 7.01: Regulation FD Disclosure
Moleculin Biotech expects to unblind efficacy data for its clinical trial by Q1 2026, with recruitment and treatment ongoing for the targeted 45-subject cohort.
Feb 18
8-K · 7.01
! Medium
Moleculin Biotech, Inc. -- 8-K 7.01: Regulation FD Disclosure
Moleculin disclosed material information to investors, potentially signaling management's effort to communicate directly about developments that could affect stock valuation and trading decisions.
Feb 18
8-K · 7.01
! Medium
Moleculin Biotech, Inc. -- 8-K 7.01: Regulation FD Disclosure
Moleculin Biotech expects a patent issuance within months, potentially strengthening its intellectual property portfolio and competitive position in the biotech sector.
Feb 17
8-K
Moleculin Biotech, Inc. -- 8-K Filing
Moleculin Biotech shareholders rejected a proposed name change, indicating potential disagreement with management's strategic direction or branding initiative.
Feb 5
Data updated apr 25, 2026 8:50pm
· Source: massive.com